NEWS

Israel’s Largest Health VC Boosts Fund to $750 Million on Virus

July 22, 2020

Israel’s largest venture capital investor in life sciences, AMoon, boosted the size of its biggest fund to $750 million after demand for new health-care technology rose during the coronavirus pandemic.

Read More

Israeli healthtech VC aMoon Velocity invests $6 million in Nectin Therapeutics

July 15, 2020

Israel’s largest healthtech venture fund, aMoon, announced an investment of $6 million in Nectin Therapeutics Ltd. via its early-stage fund, aMoon Velocity.

Read More

Israel Bolsters Antibody Tests as Second Virus Wave Threatens

July 3, 2020

Israel is fortifying its national survey of exposure to the coronavirus as a second wave of infections threatens to plunge the country back into lockdown.

Read More

‘Covid Put Everything On Steroids,’ Says Prominent Healthtech Investor

June 30, 2020

When VC aMoon was established in 2017, “the premise was to invest heavily in the convergence of technology and biology, healthcare and data,” says Dr. Yair Schindel, its Managing Partner.

Read More

NIH Partners with Israeli Startup to Generate Synthetic COVID-19 Data

June 18, 2020

Through a new partnership, the National Institutes of Health will harness Israeli startup MDClone’s platform to generate computationally-derived synthetic data directly from clinical health data aggregated across the U.S., to underpin and advance research in the fight against COVID-19.

Read More

Curesponse Secures $6M Series A for Breakthrough Precision Medicine

June 5, 2020

Curesponse, a cancer precision medicine company, has raised $6M from investors including NCL Technology Ventures (UK) and aMoon (Israel) for scaling clinical trials and international expansion to the UK.

Read More

Zebra Medical Vision Secures its 5th FDA Clearance, Making Its Vertebral Compression Fractures AI Solution Available in the U.S.

May 18, 2020

Zebra Medical Vision, the deep-learning medical imaging analytics company, announces today its fifth FDA 510(k) clearance for its Vertebral Compression Fractures (VCF) product.

Read More

Ayala Pharmaceuticals Announces Pricing of Initial Public Offering

May 7, 2020

Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations, today announced the pricing of its initial public offering of 3,666,667 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions.

Read More

Herd Immunity, or Big 2nd Wave? Israel Antibody Testing Hopes to Find Out

May 5, 2020

Yair Schindel, aMoon Managing Partner and a member of Israel’s health ministry task force on COVID-19, spoke to the The New York Times about the pandemic and Israel’s latest initiative to conduct nationwide serological testing on 100,000 citizens. Yair outlined the two likely scenarios Israel might find out as a result of the antibody testing.

Read More

resTORbio and Adicet Bio Announce Merger Agreement to Advance Allogeneic Gamma Delta CAR-T Cell Therapy Technology

April 29, 2020

resTORbio, Inc. (Nasdaq: TORC) and Adicet Bio, Inc., a privately-held biopharmaceutical company, today announced that they have entered into a definitive merger agreement to create a combined publicly-traded biotechnology company focused on the development of Adicet’s off-the-shelf allogeneic gamma delta T cell therapies for oncology and other indications.

Read More

CartiHeal raises $18.3m to support PMA trial of Agili-C implant

May 8, 2017

CartiHeal said today it raised $18.3 million in a new round of financing to support an FDA IDE-approved clinical trial of its Agili-C implant for use in repairing cartilage and osteochondral defects.

Read More

Israeli Universal Flu Vaccine Maker Receives $2.8 Million Investment

January 4, 2017

Israeli billionaire Marius Nacht is banking on Israeli bio-tech with a $2.8 million investment into BiondVax Pharmaceuticals, a clinical phase company developing a universal flu vaccine.

Read More